These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28726432)

  • 1. [News in the treatment of hypertension and dyslipidemia].
    Václavík J
    Vnitr Lek; 2017; 63(5):333-337. PubMed ID: 28726432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Notes on the HOPE-3 study].
    Soška V
    Vnitr Lek; 2016; 62(11):929-932. PubMed ID: 28128582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention: HOPE-3 trial - targeting BP and LDL-C in at-risk patients.
    Wilkins JT; Lloyd-Jones DM
    Nat Rev Cardiol; 2016 May; 13(6):315-6. PubMed ID: 27181913
    [No Abstract]   [Full Text] [Related]  

  • 4. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?].
    Soška V
    Vnitr Lek; 2021; 67(1):37-40. PubMed ID: 33752389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins in hypertension: are they a new class of antihypertensive agents?
    Feldstein CA
    Am J Ther; 2010; 17(3):255-62. PubMed ID: 19918164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How to create cooperative patient for antihypertensive and hypolipidemic therapy].
    Piťha J
    Vnitr Lek; 2017; 63(4):272-276. PubMed ID: 28520451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis.
    Wang Y; Kuang ZM; Feng SJ; Jiang L; Chen QX; Ji XY; Cheng WL; Hu HJ
    BMJ Open; 2018 May; 8(5):e019719. PubMed ID: 29858408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure and lipid target adherence in Korean patients receiving angiotensin II receptor blockers/statin regimens.
    Kim HJ; Kim E; Min KB; Min JY
    Curr Med Res Opin; 2017 Feb; 33(2):385-390. PubMed ID: 27819152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Faggiano P; Fattirolli F; Frisinghelli A; Piccioli L; Dasseni N; Silverii MV; Albricci L; D'Ambrosio G; Garrì R; Esposito L; Giallauria F
    Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31107039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient at intermediate cardiovascular risk: statins, yes! - antihypertensive therapy, maybe.
    Volpe M; Costanzi V
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e130-e132. PubMed ID: 29538162
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid, blood pressure and kidney update 2013.
    Banach M; Serban C; Aronow WS; Rysz J; Dragan S; Lerma EV; Apetrii M; Covic A
    Int Urol Nephrol; 2014 May; 46(5):947-61. PubMed ID: 24573394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].
    Bertomeu-Martínez V
    Medwave; 2016 Dec; 16(Suppl4):e6825. PubMed ID: 28055995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia.
    Bashir S; Sherwani MU; Shabbir I; Batool A
    J Ayub Med Coll Abbottabad; 2011; 23(3):97-100. PubMed ID: 23272446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of statins in endothelial dysfunction in hypertension.
    Sarkar K; Sinha AK; Mehta JL
    Curr Opin Cardiol; 2006 Jul; 21(4):316-21. PubMed ID: 16755200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.